Financial Results | Integer Holdings 2025 Q1 Revenue USD 437.39 Million Net Loss USD 22.49 Million

Integer Holdings(ITGR) posted the Q1 of its 2025 financial results on 4/24/2025, reporting total revenue of USD 437.39 million in the first quarter, up 7.26% from USD 407.80 million year over year, reporting net loss of USD 22.49 million in the first quarter, compare with the net income of USD 20.51 million in the same period last year. The EPS is USD -0.66 in the frist quater, compare with USD 0.61 last period.

[Detailed Data]

Million USD	Q1 2025	Q4 2024	Q3 2024	Q4 2024
Total Revenue	437.39	449.50	431.42	449.50
Cost of Sales	317.07	332.70	314.85	332.70
Gross Profit	120.32	116.80	116.57	116.80
Total Operating Expenses	85.57	73.00	73.13	73.00
Operating Income	34.75	43.80	43.43	43.80
Net Income	-22.49	32.70	35.44	32.70
Net Income Attributable to Common Shareholders	-22.49	32.70	35.44	32.70
EPS(USD)	-0.66	0.9749	1.05	0.9749

[Company Profile]
Integer Holdings Corporation co-inventor of the first successful implanted pacemaker, founded Greatbatch in 1970. Greatbatch, Inc. is a Delaware corporation that was incorporated in 1997. The company had its initial public offering in 2000.The Company operates its company in two reportable segments – Greatbatch Medical and Electrochem Solutions (“Electrochem”). The company's customers include large multi-national original equipment manufacturers (“OEMs”). The Greatbatch Medical segment designs and manufactures medical devices and components primarily for the Cardiac Rhythm Management (“CRM”), Neuromodulation, Vascular Access and Orthopaedic markets. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for products that incorporate Greatbatch Medical components. As a result of its strategy put in place over three years ago, Greatbatch Medical now offers its customers complete medical devices including design, development, manufacturing, regulatory submission and supporting worldwide distribution. This medical device strategy is being facilitated through the QiG Group and leverages the component technology of Greatbatch Medical and Electrochem in she company's core markets: Cardiovascular, Neuromodulation and Orthopaedic. Once the QiG Group designs and develops a medical device, it is manufactured by Greatbatch Medical.